July 2026 Research Update

Across the reports this month, asfotase alfa (an enzyme replacement therapy) was linked with improvement in bone problems when it was taken consistently, but the benefit was not always steady over time. Two family-based or single-patient reports described clear worsening when therapy stopped or when bone disease returned, followed by improvement again after therapy was restarted or adjusted. Together, these studies make the month feel less about whether the drug can work at all, and more about why some people have ups and downs while on it. [1] [2]

In an 11-year-old with perinatal hypophosphatasia, bone X-rays first improved on asfotase alfa and later showed rickets returning during a period when neutralizing antibodies were detected (antibodies that can block a medicine from working well). After the dose was increased and treatment continued, rickets nearly disappeared again and the neutralizing antibodies later became negative, although this is a single case and cannot prove cause and effect. The case also noted injection-site lipodystrophy (changes in fat under the skin where injections are given) and nephrocalcinosis (calcium deposits in the kidneys) with normal kidney function. [2]

A 17-year follow-up of three affected siblings reported substantial improvement in one sister who received asfotase alfa for about 3.5 years, including better clinical and functional measures and quality of life. The report also described deterioration after an unplanned stop in therapy, with recovery after treatment was resumed, reinforcing that interruption can matter for some individuals. This case series also documented osteomalacia (soft bone) on bone tissue testing, connecting symptoms to a clear bone finding in that family. [1]

One retrospective clinic study primarily focused on diagnosis, but it included limited treatment information from a single person who started asfotase alfa. That patient showed partial skeletal response with healing of a pseudofracture, while CPPD (a crystal-related joint disease) persisted, and a CPPD flare was noted during treatment. This adds a small reminder that different problems linked to low ALP can move in different directions even in the same person. [3]

For patients and caregivers, this month mainly adds practical context for why symptoms or X-rays might improve, then worsen, then improve again during asfotase alfa treatment. The evidence here is mostly single-patient or family reports, so it is best viewed as real-world learning rather than a guarantee of what will happen for any one person. What became clearer is that immune response (neutralizing antibodies) and treatment interruption are two plausible explanations reported for changing response over time, and that some complications (like crystal-related joint problems) may not improve even if a bone lesion heals. What remains uncertain is how common these patterns are, and how well antibody testing predicts day-to-day outcomes outside of individual cases. [2] [1] [3]

This month strengthened a practical idea: a low alkaline phosphatase (ALP) result can be an overlooked clue, and adding a few related lab markers may help sort out who is more likely to have an ALPL-related cause. One large hospital review found that unexplained persistently low ALP was very uncommon, yet the people who had it often had symptoms that fit what many patients describe in adult hypophosphatasia. A second study from a specialty clinic showed that adults with certain ALPL genetic variants had a different pattern of ALP-related markers than people with low ALP but no ALPL variant detected. [4] [3]

In the Riyadh hospital review, only 25 adults (0.01% of those tested) had unexplained persistently low ALP after exclusions, and most had muscle and joint symptoms, fatigue, and many had fractures. Dental abnormalities were also common, and about 25% showed family clustering, which can be a clue that genetics may play a role. The authors also noted that none of these patients had documentation in the electronic record that the persistently low ALP was recognized or that hypophosphatasia was considered. [4]

In the University of Tokyo clinic study, adults with persistent low ALP were grouped by ALPL genetic findings, including whether a variant was thought likely to interfere with the normal enzyme (dominant-negative effect) or not. People with monoallelic variants without dominant-negative effect looked different from variant-negative individuals on multiple ALP-related markers, and a model that combined ALP with two substrate markers (a urine marker called PEA and a blood marker called PPi) had high reported accuracy for separating these groups in that clinic sample. This supports the idea that low ALP alone may not tell the whole story, and that a pattern of markers can be more informative than a single value. [3]

For patients, these studies mainly matter for understanding recognition and workup rather than changing treatment right now. The Riyadh review suggests that persistently low ALP may be missed in routine care even when people have fractures, pain, fatigue, or dental issues, while the Tokyo study suggests that adding specific ALP-related markers may better distinguish genetic hypophosphatasia from other reasons ALP can be low. What remains uncertain is how well the Tokyo clinic model works in other hospitals and populations, because it has not been externally validated in the summary provided. Taken together, this month helps clarify that adult low-ALP pathways are moving toward more structured lab patterns plus genetics, rather than relying on ALP alone. [4] [3]

This month highlighted a recurring real-world complication: finding an ALPL variant does not always mean it explains every symptom. Across multiple case reports, people had an ALPL variant plus another genetic diagnosis, and the most striking problems (growth arrest, severe muscle weakness, or intense pain) were attributed mainly to the other condition or to an interaction that is still hypothetical. The main addition this month is a clearer warning against "one-gene, one-explanation" thinking when the clinical picture seems more severe or different than expected. [5] [6] [7]

In a 16-year-old girl with severe disproportionate short stature and growth arrest, testing found a pathogenic ALPL variant and an ACAN variant of uncertain significance (a cartilage gene sometimes linked to growth plate problems). The authors attributed the growth pattern primarily to ACAN-related growth plate dysfunction, with the ALPL finding considered incidental and with minimal clinical expression, even though ALP levels were persistently low and there were enamel abnormalities. This case adds nuance for families who receive an ALPL result during broader genetic testing for growth. [5]

Two related cases described a woman with confirmed hypophosphatasia who had much more severe proximal muscle weakness than would be expected from bone disease alone, and muscle imaging suggested a separate muscle disorder. Genetic testing confirmed COL6-related muscular dystrophy in addition to hypophosphatasia, and the report emphasized that a second neuromuscular diagnosis should be considered when weakness is disproportionate. The daughter carried the ALPL variant and had carrier status for the COL6 condition, showing how mixed genetic findings can appear within one family. [6]

A 40-year-old woman with Pyle disease (from homozygous SFRP4 variants) also had a heterozygous ALPL variant of uncertain significance (her normal vitamin B6 level argued against overt hypophosphatasia) and severe chronic bone pain that seemed out of proportion to some imaging findings. The report described mainly cortical bone loss, bone marrow edema on MRI, very low bone alkaline phosphatase, and low body fat, and it proposed an exploratory model in which SFRP4-related bone changes and ALPL variation could interact. Because this is a single case with a hypothesis-generating explanation, it mainly serves as a signal of complexity rather than a proven mechanism. [7]

For patients and caregivers, these reports may be most useful when symptoms do not match expectations, such as unusually severe short stature, weakness, or pain. The level of evidence is early because these are individual cases, but they help clarify that hypophosphatasia can coexist with other genetic conditions, and that the most disabling symptom may come from the coexisting condition. What remains uncertain is how often this happens and which symptom patterns should trigger broader testing, since the reports do not provide frequency estimates. In the near term, this information mostly affects understanding and diagnosis rather than offering new proven treatments. [5] [6] [7]